Back to results
US 2026/0042850 A1Published application
Anti c-met antibodies
AssigneeCentessa Pharmaceuticals (UK) Limited
InventorWilliam James Jonathan FINLAY
Life of this patent
Estimating the term…
Abstract
Provided herein are antibody molecules that bind specifically to C-MET and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.
Claims21
-40. (canceled)
An anti-C-MET antibody or an antigen-binding portion thereof, wherein the antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein
- (a) the VH region amino acid sequence comprises HCDR1 of GYTFTSYSMH (SEQ ID NO:
- 78), HCDR2 of MGWINPNGGLTNYAQKFRG (SEQ ID NO:
- 79), and HCDR3 of EEITTEFDY (SEQ ID NO:
- 80);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO:
- 57), LCDR2 of RASTRET (SEQ ID NO:
- 77), and LCDR3 of QQSKESPLT (SEQ ID NO:
- 47);
- (b) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGWINPNNGSTNYAQKFQG (SEQ ID NO:
- 81), and HCDR3 of SEITTDFDY (SEQ ID NO:
- 55);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO:
- 37), LCDR2 of RGSTRES (SEQ ID NO:
- 38), and LCDR3 of QQSKSDPLT (SEQ ID NO:
- 76);
- (c) the VH region amino acid sequence comprises HCDR1 of GYIFTAYSMH (SEQ ID NO:
- 83), HCDR2 of MGIIKPSNGSTNYAQKFQG (SEQ ID NO:
- 84), and HCDR3 of AEITTEFDY (SEQ ID NO:
- 85);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVESYAQSYLH (SEQ ID NO:
- 46), LCDR2 of RGSTRES (SEQ ID NO:
- 38), and LCDR3 of QQSKEEPLT (SEQ ID NO:
- 82);
- (d) the VH region amino acid sequence comprises HCDR1 of GYIFTSYTMH (SEQ ID NO:
- 48), HCDR2 of MGWIKPNNGSASYAQKFQG (SEQ ID NO:
- 86), and HCDR3 of SEITTEEDY (SEQ ID NO:
- 241);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVDSYANSYLH (SEQ ID NO:
- 51), LCDR2 of RGSTRES (SEQ ID NO:
- 38), and LCDR3 of QQSKSEPLT (SEQ ID NO:
- 39);
- (e) the VH region amino acid sequence comprises HCDR1 of GYIFTAYSMH (SEQ ID NO:
- 83), HCDR2 of MGWIKPNNGSTNYAQKFQG (SEQ ID NO:
- 87), and HCDR3 of TEITTEFDY (SEQ ID NO:
- 88);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVDSYANSYLH (SEQ ID NO:
- 51), LCDR2 of RGSTRET (LCDR2;
- SEQ ID NO:
- 56), and LCDR3 of QQSKSDPLT (SEQ ID NO:
- 76);
- (f) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGWINPSGGSTSYAQKFQG (SEQ ID NO:
- 40), and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO:
- 57), LCDR2 of RGSTRET (SEQ ID NO:
- 56), and LCDR3 of QQSGSSPLT (SEQ ID NO:
- 89);
- (g) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGWINPSGGSTSYAQKFQG (SEQ ID NO:
- 40), and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO:
- 57), LCDR2 of RGSTRET (SEQ ID NO:
- 56), and LCDR3 of QQYGSSPLT (SEQ ID NO:
- 90);
- (h) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO:
- 35), and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO:
- 57), LCDR2 of RGSTRET (SEQ ID NO:
- 56), and LCDR3 of QQSGSSPLT (SEQ ID NO:
- 89);
- (i) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO:
- 35), and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO:
- 57), LCDR2 of RGSTRET (SEQ ID NO:
- 56), and LCDR3 of QQYGSSPLT (SEQ ID NO:
- 90);
- (j) the VH region amino acid sequence comprises HCDR1 of GYTFTSYAMH (SEQ ID NO:
- 41), HCDR2 of MGWINPSGGSTSYAQKFQG (SEQ ID NO:
- 40), and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO:
- 37), LCDR2 of RGSTRES (SEQ ID NO:
- 38), and LCDR3 of QQSKSEPLT (SEQ ID NO:
- 39);
- (k) the VH region amino acid sequence comprises HCDR1 of GYTFTSYAMH (SEQ ID NO:
- 41), HCDR2 of MGWINPSGGSTSYAQKFQG (SEQ ID NO:
- 40), and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO:
- 57), LCDR2 of RGSTRET (SEQ ID NO:
- 56), and LCDR3 of QQSGSSPLT (SEQ ID NO:
- 89);
- or
- (l) the VH region amino acid sequence comprises HCDR1 of GYTFTSYAMH (SEQ ID NO:
- 41), HCDR2 of MGWINPSGGSTSYAQKFQG (SEQ ID NO:
- 40), and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYAQSYLH (SEQ ID NO:
- 57), LCDR2 of RGSTRET (SEQ ID NO:
- 56), and LCDR3 of QQYGSSPLT (SEQ ID NO:
- 90).
95 more elements
Dependencies are inferred from the claim text.